STOCK TITAN

[Form 4] Cingulate Inc. Warrants Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Cingulate Inc. (CING) filed a Form 4 reporting two stock-option grants to Raul R. Silva, EVP & Chief Scientific Officer.

  • Grant 1: 1,000 options to buy common stock at an exercise price of $4.30 per share. Grant and first exercisable date: 03/31/2025; expiration: 03/31/2035.
  • Grant 2: 1,000 options at an exercise price of $4.07 per share. Grant and first exercisable date: 06/30/2025; expiration: 06/30/2035.

Both grants were made pursuant to Dr. Silva’s employment agreement and are held directly. No open-market purchases or sales of common stock were reported, and Table I shows no changes in non-derivative holdings. Post-transaction, Dr. Silva beneficially owns 1,000 derivative securities in each grant line, representing incentive alignment but a modest absolute share count.

Cingulate Inc. (CING) ha presentato un Modulo 4 segnalando due assegnazioni di stock option a Raul R. Silva, EVP e Chief Scientific Officer.

  • Assegnazione 1: 1.000 opzioni per acquistare azioni ordinarie a un prezzo di esercizio di 4,30 $ per azione. Data di assegnazione e prima data di esercizio: 31/03/2025; scadenza: 31/03/2035.
  • Assegnazione 2: 1.000 opzioni a un prezzo di esercizio di 4,07 $ per azione. Data di assegnazione e prima data di esercizio: 30/06/2025; scadenza: 30/06/2035.

Entrambe le assegnazioni sono state effettuate in base al contratto di lavoro del Dr. Silva e sono detenute direttamente. Non sono stati segnalati acquisti o vendite di azioni ordinarie sul mercato aperto e la Tabella I non mostra variazioni nelle partecipazioni non derivate. Dopo la transazione, il Dr. Silva detiene beneficiariamente 1.000 titoli derivati per ciascuna linea di assegnazione, indicando un allineamento di incentivi ma un numero assoluto di azioni modesto.

Cingulate Inc. (CING) presentó un Formulario 4 reportando dos concesiones de opciones sobre acciones a Raul R. Silva, EVP y Director Científico.

  • Concesión 1: 1,000 opciones para comprar acciones comunes a un precio de ejercicio de $4.30 por acción. Fecha de concesión y primera fecha de ejercicio: 31/03/2025; expiración: 31/03/2035.
  • Concesión 2: 1,000 opciones a un precio de ejercicio de $4.07 por acción. Fecha de concesión y primera fecha de ejercicio: 30/06/2025; expiración: 30/06/2035.

Ambas concesiones se hicieron conforme al contrato laboral del Dr. Silva y se mantienen directamente. No se reportaron compras o ventas de acciones comunes en el mercado abierto y la Tabla I no muestra cambios en las tenencias no derivadas. Tras la transacción, el Dr. Silva posee beneficiariamente 1,000 valores derivados en cada línea de concesión, lo que representa alineación de incentivos pero un conteo absoluto modesto de acciones.

Cingulate Inc. (CING)Raul R. Silva, EVP 및 최고과학책임자에게 두 건의 스톡 옵션 부여를 보고하는 Form 4를 제출했습니다.

  • 부여 1: 보통주 1,000주를 주당 $4.30의 행사가격으로 매수할 수 있는 옵션. 부여 및 최초 행사 가능일: 2025년 3월 31일; 만료일: 2035년 3월 31일.
  • 부여 2: 주당 $4.07의 행사가격으로 1,000주 옵션. 부여 및 최초 행사 가능일: 2025년 6월 30일; 만료일: 2035년 6월 30일.

두 부여 모두 Silva 박사의 고용 계약에 따라 이루어졌으며 직접 보유 중입니다. 공개 시장에서의 보통주 매매는 보고되지 않았으며, 표 I에는 비파생 보유 변동이 없습니다. 거래 후 Silva 박사는 각 부여 라인에서 1,000개의 파생 증권을 실질 소유하여 인센티브 정렬은 이루어졌으나 절대 주식 수는 적은 편입니다.

Cingulate Inc. (CING) a déposé un formulaire 4 signalant deux attributions d’options d’achat d’actions à Raul R. Silva, EVP et Directeur Scientifique.

  • Attribution 1 : 1 000 options d’achat d’actions ordinaires à un prix d’exercice de 4,30 $ par action. Date d’attribution et première date d’exercice : 31/03/2025 ; expiration : 31/03/2035.
  • Attribution 2 : 1 000 options à un prix d’exercice de 4,07 $ par action. Date d’attribution et première date d’exercice : 30/06/2025 ; expiration : 30/06/2035.

Les deux attributions ont été effectuées conformément au contrat de travail du Dr Silva et sont détenues directement. Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été signalé, et le tableau I ne montre aucun changement dans les avoirs non dérivés. Après la transaction, le Dr Silva détient effectivement 1 000 titres dérivés pour chaque attribution, ce qui reflète un alignement des incitations mais un nombre absolu d’actions modeste.

Cingulate Inc. (CING) reichte ein Formular 4 ein, in dem zwei Aktienoptionszuteilungen an Raul R. Silva, EVP & Chief Scientific Officer, gemeldet wurden.

  • Zuteilung 1: 1.000 Optionen zum Kauf von Stammaktien zu einem Ausübungspreis von 4,30 $ pro Aktie. Zuteilungs- und erstes Ausübungsdatum: 31.03.2025; Ablaufdatum: 31.03.2035.
  • Zuteilung 2: 1.000 Optionen zu einem Ausübungspreis von 4,07 $ pro Aktie. Zuteilungs- und erstes Ausübungsdatum: 30.06.2025; Ablaufdatum: 30.06.2035.

Beide Zuteilungen erfolgten gemäß dem Arbeitsvertrag von Dr. Silva und werden direkt gehalten. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und Tabelle I zeigt keine Änderungen bei den nicht-derivativen Beständen. Nach der Transaktion besitzt Dr. Silva wirtschaftlich 1.000 derivative Wertpapiere pro Zuteilung, was eine Anreizangleichung darstellt, aber eine eher geringe absolute Aktienanzahl.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Small option grants to an officer; routine incentive alignment, limited market impact.

The reported grants total 2,000 options with 10-year lives and strike prices in the low-$4 range, roughly aligning with typical at-the-money compensation awards for emerging biopharma executives. Because no common shares were bought or sold for cash, there is no immediate liquidity signal. The size is immaterial relative to most public floats, so market impact should be negligible. Nonetheless, the issuance extends retention incentives and ties compensation to long-term shareholder value.

Cingulate Inc. (CING) ha presentato un Modulo 4 segnalando due assegnazioni di stock option a Raul R. Silva, EVP e Chief Scientific Officer.

  • Assegnazione 1: 1.000 opzioni per acquistare azioni ordinarie a un prezzo di esercizio di 4,30 $ per azione. Data di assegnazione e prima data di esercizio: 31/03/2025; scadenza: 31/03/2035.
  • Assegnazione 2: 1.000 opzioni a un prezzo di esercizio di 4,07 $ per azione. Data di assegnazione e prima data di esercizio: 30/06/2025; scadenza: 30/06/2035.

Entrambe le assegnazioni sono state effettuate in base al contratto di lavoro del Dr. Silva e sono detenute direttamente. Non sono stati segnalati acquisti o vendite di azioni ordinarie sul mercato aperto e la Tabella I non mostra variazioni nelle partecipazioni non derivate. Dopo la transazione, il Dr. Silva detiene beneficiariamente 1.000 titoli derivati per ciascuna linea di assegnazione, indicando un allineamento di incentivi ma un numero assoluto di azioni modesto.

Cingulate Inc. (CING) presentó un Formulario 4 reportando dos concesiones de opciones sobre acciones a Raul R. Silva, EVP y Director Científico.

  • Concesión 1: 1,000 opciones para comprar acciones comunes a un precio de ejercicio de $4.30 por acción. Fecha de concesión y primera fecha de ejercicio: 31/03/2025; expiración: 31/03/2035.
  • Concesión 2: 1,000 opciones a un precio de ejercicio de $4.07 por acción. Fecha de concesión y primera fecha de ejercicio: 30/06/2025; expiración: 30/06/2035.

Ambas concesiones se hicieron conforme al contrato laboral del Dr. Silva y se mantienen directamente. No se reportaron compras o ventas de acciones comunes en el mercado abierto y la Tabla I no muestra cambios en las tenencias no derivadas. Tras la transacción, el Dr. Silva posee beneficiariamente 1,000 valores derivados en cada línea de concesión, lo que representa alineación de incentivos pero un conteo absoluto modesto de acciones.

Cingulate Inc. (CING)Raul R. Silva, EVP 및 최고과학책임자에게 두 건의 스톡 옵션 부여를 보고하는 Form 4를 제출했습니다.

  • 부여 1: 보통주 1,000주를 주당 $4.30의 행사가격으로 매수할 수 있는 옵션. 부여 및 최초 행사 가능일: 2025년 3월 31일; 만료일: 2035년 3월 31일.
  • 부여 2: 주당 $4.07의 행사가격으로 1,000주 옵션. 부여 및 최초 행사 가능일: 2025년 6월 30일; 만료일: 2035년 6월 30일.

두 부여 모두 Silva 박사의 고용 계약에 따라 이루어졌으며 직접 보유 중입니다. 공개 시장에서의 보통주 매매는 보고되지 않았으며, 표 I에는 비파생 보유 변동이 없습니다. 거래 후 Silva 박사는 각 부여 라인에서 1,000개의 파생 증권을 실질 소유하여 인센티브 정렬은 이루어졌으나 절대 주식 수는 적은 편입니다.

Cingulate Inc. (CING) a déposé un formulaire 4 signalant deux attributions d’options d’achat d’actions à Raul R. Silva, EVP et Directeur Scientifique.

  • Attribution 1 : 1 000 options d’achat d’actions ordinaires à un prix d’exercice de 4,30 $ par action. Date d’attribution et première date d’exercice : 31/03/2025 ; expiration : 31/03/2035.
  • Attribution 2 : 1 000 options à un prix d’exercice de 4,07 $ par action. Date d’attribution et première date d’exercice : 30/06/2025 ; expiration : 30/06/2035.

Les deux attributions ont été effectuées conformément au contrat de travail du Dr Silva et sont détenues directement. Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été signalé, et le tableau I ne montre aucun changement dans les avoirs non dérivés. Après la transaction, le Dr Silva détient effectivement 1 000 titres dérivés pour chaque attribution, ce qui reflète un alignement des incitations mais un nombre absolu d’actions modeste.

Cingulate Inc. (CING) reichte ein Formular 4 ein, in dem zwei Aktienoptionszuteilungen an Raul R. Silva, EVP & Chief Scientific Officer, gemeldet wurden.

  • Zuteilung 1: 1.000 Optionen zum Kauf von Stammaktien zu einem Ausübungspreis von 4,30 $ pro Aktie. Zuteilungs- und erstes Ausübungsdatum: 31.03.2025; Ablaufdatum: 31.03.2035.
  • Zuteilung 2: 1.000 Optionen zu einem Ausübungspreis von 4,07 $ pro Aktie. Zuteilungs- und erstes Ausübungsdatum: 30.06.2025; Ablaufdatum: 30.06.2035.

Beide Zuteilungen erfolgten gemäß dem Arbeitsvertrag von Dr. Silva und werden direkt gehalten. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und Tabelle I zeigt keine Änderungen bei den nicht-derivativen Beständen. Nach der Transaktion besitzt Dr. Silva wirtschaftlich 1.000 derivative Wertpapiere pro Zuteilung, was eine Anreizangleichung darstellt, aber eine eher geringe absolute Aktienanzahl.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Silva Raul R.

(Last) (First) (Middle)
1901 W. 47TH PLACE

(Street)
KANSAS CITY KS 66205

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cingulate Inc. [ CING ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP and CSO
3. Date of Earliest Transaction (Month/Day/Year)
03/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to Buy) $4.3 03/31/2025(1) A 1,000 03/31/2025 03/31/2035 Common Stock 1,000 $0 1,000 D
Stock Option (right to Buy) $4.07 06/30/2025(1) A 1,000 06/30/2025 06/30/2035 Common Stock 1,000 $0 1,000 D
Explanation of Responses:
1. The option was granted pursuant to the terms of Dr. Silva's Employment Agreement, as amended.
/s/ Shane J. Schaffer, Attorney-in-Fact 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CING insider Raul R. Silva report on the Form 4?

He received two stock-option grants totaling 2,000 options with strikes of $4.30 and $4.07 per share.

Were any Cingulate Inc. common shares bought or sold by the insider?

No. The filing shows no acquisitions or disposals of non-derivative common stock.

What are the exercise and expiration dates of the options?

Grant 1: exercisable 03/31/2025, expires 03/31/2035. Grant 2: exercisable 06/30/2025, expires 06/30/2035.

How many derivative securities does Dr. Silva own after these grants?

The filing lists 1,000 options under each grant line, held directly.

Does the filing indicate a 10b5-1 trading plan?

The form includes the new Rule 10b5-1(c) checkbox, but it is not marked as selected.
Cingulate

NASDAQ:CINGW

CINGW Rankings

CINGW Latest News

CINGW Latest SEC Filings

CINGW Stock Data

3.83M
Biotechnology
Pharmaceutical Preparations
Link
United States
KANSAS CITY